TrialX
Image

Study KBP-2020-CPHG Documenting New Cases of Primary Lung Cancer (PLC) Diagnosed in Respiratory Medicine Departments and Lung Cancer Units at General Hospitals From January 1st to December 31st 2020

Study KBP-2020-CPHG Documenting New Cases of Primary Lung Cancer (PLC) Diagnosed in Respiratory Medicine Departments and Lung Cancer Units at General Hospitals From January 1st to December 31st 2020

Recruiting
18 years and older
All
Phase N/A

Overview

Twenty years after KBP-2000-CPHG study and ten years after KBP-2010-CPHG study, the CPHG proposes to conduct a new epidemiological study on primary PLC in order to evaluate and analyze the changes that have occurred over the last decade.

Primary endpoint:

Estimate 1-year- and 5-year-mortality rates in patients with PLC.

Secondary endpoints:

  • Describe PLC patient population managed by pulmonologists at French General Hospitals in 2020
  • Describe PLC diagnostic and therapeutic management by pulmonologists at French General Hospitals in 2020 and compare them to KBP-2000-CPHG and KBP-2010-CPHG studies
  • Estimate prognostic factors
  • Compare patient and tumor characteristics to those observed for KBP-2010-CPHG and KBP-2000-CPHG studies
  • Compare observed survival rates to those reported for KBP-2000-CPHG and KBP-2010-CPHG studies

Eligibility

Inclusion Criteria:

  • Age 18 years
  • Primary Lung Cancer histologically (or cytologically or presence of a mutation on liquid biopsy with compatible imaging) proven between January 1st and December 31st, 2020*
  • Follow-up by a lung specialist at a General Hospital
  • Oral informed consent * date of collected sample

Exclusion Criteria:

  • Age < 18 years
  • Secondary lung cancer
  • Recurrence of same histological type PLC- left to the investigator discretion according to the clinic and the imagery
  • Previous enrolment in the study
  • Freedom deprived patient following a legal or administrative decision
  • Patient unable to give his(her) consent

Study details
    Pulmonary Disease
    Lung Neoplasm
    lung cancer
    lung cancer

NCT04402099

Collège des Pneumologues des Hôpitaux Généraux

16 February 2024

Contact a study center
Step 1 Get in touch with the nearest study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.